1 Title

2 OLFACTORY TRAINING EFFICIENCY IN POST-COVID-19 PERSISTENT OLFACTORY DISORDERS

- 3
- 4 Running title
- 5 OLFACTORY TRAINING EFFICIENCY IN COVID-19 SMELL LOSS
- 6
- 7 Authors
- 8 Clair Vandersteen<sup>1,2</sup>, Magali Payne<sup>2,3</sup>, Louise-Émilie Dumas<sup>2,4</sup>, Élisa Cancian<sup>1</sup>, Alexandra
- 9 Plonka<sup>2,5,6</sup>, Grégoire D'Andrea<sup>1</sup>, David Chirio<sup>7</sup>, Élisa Demonchy<sup>7</sup>, Karine Risso<sup>7</sup>, Florence
- 10 Askenazy-Gittard<sup>2,4</sup>, Charles Savoldelli<sup>1</sup>, Nicolas Guevara<sup>1</sup>, Philippe Robert<sup>2,3,6</sup>, Laurent
- 11 Castillo<sup>1</sup>, Valeria Manera<sup>2,3</sup>, Auriane Gros<sup>2,3,6</sup>
- 12
- 13 Affiliation
- 14 <sup>1</sup>Institut Universitaire de la Face et du Cou, 31 Avenue de Valombrose, 06100, Centre Hospitalier Universitaire,
- 15 Université Côte d'Azur, Nice, Alpes-Maritimes, France
- 16 <sup>2</sup>Université Côte d'Azur, laboratoire CoBTeK, Nice, France
- <sup>3</sup>Université Côte d'Azur, Département d'Orthophonie de Nice, UFR Médecine, Nice, France.
- 18 <sup>4</sup>Hôpitaux Pédiatriques de Nice CHU-LENVAL, 57 Avenue de la Californie, 06200, Centre Hospitalier
- 19 Universitaire, Université Côte d'Azur, Nice, Alpes-Maritimes, France
- 20 <sup>5</sup>Institut NeuroMod, INRIA Centre de recherche Sophia Antipolis, 2004 Route des Lucioles, 06902, Université
- 21 Côte d'Azur, Sophia Antipolis, Alpes-Maritimes, France
- 22 <sup>6</sup>Centre Hospitalier Universitaire de Nice, Service Clinique Gériatrique du Cerveau et du Mouvement, Nice,
- 23 France
- <sup>7</sup>Département de médecine infectiologique, hôpital de l'archet, 151 route de Saint-Antoine, 06200, Centre
- 25 Hospitalier Universitaire, Université Côte d'Azur, Nice, Alpes-Maritimes, France
- 26

- 27 KEY WORDS:
- 28 COVID-19, OLFACTION DISORDERS, OLFACTORY TRAINING, PAROMIA
- 29 CORRESPONDING AUTHOR
- 30
- 31 Dr. Clair Vandersteen, M.D
- 32 ENT surgery departement of Institut Universitaire de la Face et du Cou (IUFC)
- 33 31 Avenue de Valombrose
- 34 Centre Hospitalier Universitaire (CHU)
- 35 Université Côte D'Azur (UCA)
- 36 06100 NICE France
- 37
- 38 Tel : 04 92 03 17 61
- 39 Fax : 04 92 03 17 05
- 40 Mail : <u>vandersteen.c@chu-nice.fr</u>
- 41 ORCID: 0000-0001-5597-2
- 42
- 43 CONFLICT OF INTEREST
- 44 None declared
- 45 FUNDING
- 46 None declared
- 47

#### 48 ABSTRACT

49

50 **Background** - Persistent post-viral olfactory disorders (PPVOD) are widely reported after a 51 COVID-19 and estimate to 30% one year after infection. Parosmias are the main qualitative 52 dysosmia associated with olfaction recovery. No treatment is, to date, significantly efficient 53 on PPVOD except olfactory training (OT). The main objective of this work was to evaluate OT 54 efficiency on post-COVID-19 PPVOD.

55 *Methods* - Consecutive patients consulting to the ENT department with post-COVID-19

56 PPVOD were included after mainly clinical examination, the complete Sniffin' Stick Test (TDI),

57 the short version of the Questionnaire of olfactory disorders and the SF-36. Patients were

58 trained to practice a self-olfactory training (professional manufactured olfactory training kit)

twice a day for 6 months before coming back and undergo the same complete evaluation.

60 **Results** - Forty-three patients were included and performed 3,5 months of OT in average.

61 There was a significant improvement in the mean TDI score increasing from 24,7 (±8,9)

62 before the OT to 30,9 (±9,8) (p<0,001). Parosmias increased significantly from 8 (18,6%) to

63 27 (62.8%) (p<0,001). Based on normative data divided by sex and age, a significant increase

64 in the number of normosmic participants was only found for the Threshold values (p<0,001).

65 Specific and general olfaction-related quality of life improved after the OT.

*Conclusions* - OT seems to be efficient in post-COVID-19 PPVOD, probably on the peripheral
 regenerative part of the olfactory recovery. Future therapeutic strategies may focus on the
 central aspects of the post-COVID-19 PPVOD.

69

70

## 71 INTRODUCTION

72 Long persistent olfactory complaint is widely reported after an acute, mild, or 73 moderate, COVID-19 infection. Indeed, a complete but subjective olfaction recovery is only reported in 40 to  $63\%^{(1-3)}$  and  $70\%^{(4)}$  of patients, respectively 6 and 12 months after COVID-74 19. Interestingly, olfactory psychophysical tests results are better than subjective smell 75 assessments, showing 73% to 95% normosmic patients after 6 months<sup>(5,6)</sup>. Some authors 76 77 suggested that these remaining olfactory complaining patients, with no recovery 18 months after acute phase<sup>(7)</sup>, could be permanently impaired. Parosmias are the main qualitative 78 dysosmias associated with COVID-19 olfactory recovery and occurs in 18% to 49%<sup>(3,7,8)</sup> of 79 80 patients 2,5 months after the acute phase of infection. Parosmias affects 20% of normosmic patients<sup>(3)</sup> and contributes to the discrepancy between subjective impairment and olfactory 81 82 psychophysical tests.

Long lasting olfactory loss leads to a quality of life(QoL)<sup>(8)</sup> impairment, bad diet 83 habits<sup>(9)</sup>, changes in social and personal relations<sup>(10)</sup>, psychiatric disorders (such as 84 depression<sup>(11)</sup>), anxiety or anorexia<sup>(12)</sup> and its nutritional consequences<sup>(13)</sup>, cognitive 85 impairment<sup>(10)</sup>, or increase of hazardous events incidence<sup>(14)</sup>. Thus they have to be managed. 86 Many treatments<sup>(15)</sup> have been tried to get an olfaction recovery without significant results, 87 88 including vitamins, minerals, corticosteroids, as well in COVID-19 as reported in a recent Cochrane living review<sup>(16)</sup>. Meanwhile, olfactory training (OT), as described by Pr. Thomas 89 Hummel<sup>(17)</sup>, remains the best treatment for persistent post-viral olfactory disorder 90 (PPVOD)<sup>(18)</sup>. Indeed, in PPVOD, OT systematically improve the Minimal Clinically Important 91 Difference (MCID) of the complete Sniffin' Stick Test score (TDI:  $+6^{(17)}$ ) in 30 to 68% of cases 92 (OR=2.77)<sup>(18)</sup>. However, the effectiveness of OT on COVID-19 patients with PPVOD is still 93 94 unknown. The main objective of this work was to evaluate OT on PPVOD after a COVID-19.

#### 95 MATERIAL AND METHODS

96

#### 97 **Population**

98 The study was approved by the institutional review board of the Nice University 99 Hospital (CNIL number: 412) and registered with a ClinicalTrials.gov number (ID: 100 NCT04799977). Since March 2020, we prospectively enrolled patients at ENT division of Nice 101 University Hospital until December 2020. All were contaminated by COVID-19 with 102 persistent olfactory disorders lasting more than 6 weeks (3 to 15 months). Patients where 103 mainly self-referred or referred by general practitioners or colleagues. Patients had either a RT-PCR-proven SARS-CoV-2 diagnosis or a CT-proven SARS-CoV-2 diagnosis secondarily 104 105 confirmed by serology. We retroprospectively extracted patients' demographic data and 106 clinical features including subjective taste impairment, subjective olfactive impairment 107 (qualitative and quantitative dysosmia), a visual analogue scale (VAS) for the subjective 108 assessment of olfactory recovery (ranging from 0% to 100%), weight (measured at home in the previous week on a personal scale), a nasofibroscopy (assessing nasal cavity patency and 109 differential diagnosis), an evaluation of olfactory loss using Sniffin' Sticks Test<sup>®</sup> (SST)<sup>(19)</sup>, the 110 111 completion of the French short version of Questionnaire of Olfactory Disorders (Short-QOD-NS<sup>(20)</sup> and the completion of the French SF-36<sup>(21)</sup>. Patients were trained to a daily use of the 112 113 OT protocol (detailed below) for 6 months. A second consultation (6 months ± 15days) after 114 OT allowed to assess a second time all the same elements except nasofibroscopy. We finally 115 retrieved OT compliance through a score calculated according to this formula: (((number of 116 OT weeks done/24) - (number of OT sessions missed per week / 14))/ number of OT weeks 117 done) \* 100.

118

119

## 120 **Objective olfactory dysfunction**

121 Olfactory function was assessed using Sniffin' Sticks test, a validated psychophysical 122 test that included a phenyl-ethyl alcohol (PEA) odor Threshold detection (T), an odor 123 Discrimination (D) and an odor Identification (I) test. The detailed procedure has already been detailed previously<sup>(22)</sup>. Results from the three tests were summed up to a composite 124 score, the "TDI". As described by the last update of TDI normative values<sup>(19)</sup>, normosmia. 125 126 hyposmia and anosmia was respectively defined by a TDI $\geq$ 30.75, 30.5 $\geq$ TDI $\geq$ 16.25, and TDI<16. Concerning isolated T, D and I values, a normal or reduced olfactory function, 127 related to gender and age, was respectively defined as  $\geq$ 10th percentile and <10th percentile 128 subdimension score based on<sup>(19)</sup>. 129

130

#### 131 Olfactory training

OT was here based on Hummel protocol<sup>(17)</sup>, whose regenerative properties on 132 olfactory neurons, olfactory cortex connectivity and olfactory scores are widely reported in 133 the literature<sup>(15, 18, 23)</sup>. Therefore, the protocol was explained to patients. It involved 6-months 134 135 olfactory training with daily odors exposure, twice a day (2 sessions), with 2 different 136 random odors of the kit, the morning and the evening (four different odors per day). We decided to run the olfactive training for 6 months as it is described<sup>(24)</sup> as more effective than 137 12 weeks firstly described protocol<sup>(17)</sup>, especially since odors are renewed every 3 months<sup>(15)</sup>. 138 Patients were well-informed, once all odors used at least one time, to try to recognize by 139 140 blindly sniffing them. To improve compliance and ludic aspects of the OT, we used other 141 odors than the 4 common ones (Phenylethyl alcohol [Rose], Eucalyptol [Eucalyptus], Citronellal [Citronella], Eugenol [Clove])<sup>(17)</sup>. We used an olfaction training kit, produced 142

specially for this purpose by local industry, including 11 small pots of scented wax (10g), impregnated with 15% of dill, thyme, cinnamon, cloves, coriander leaf, vinegar, cumin, lavender, coffee, vanilla, or mint. We used different type of odors because there is no significant difference in olfaction improvement using simple or complex odors, or combination of both<sup>(25)</sup>.

148

## 149 **Olfactory quality of life**

The olfactory QoL was assessed using the French validated Short-QOD-NS<sup>(20)</sup> self-150 151 questionnaire (2 min) which is based on negative statements from the Questionnaire of Olfactory Disorders (QOD), but shorter, allowing an increase of the response rate and 152 153 reducing the patient's mental load when completing the questionnaire. These negative 154 statements of QOD has been shown to be more correlated with the results of psychophysical olfactory tests (SST)<sup>(26)</sup>. The Short-QOD-NS<sup>(27)</sup> evaluate the 7 most relevant questions related 155 156 to social aspects (n = 3), eating (n = 2), anxiety (n = 1) and annoyance (n = 1) following an 157 olfactory loss. The score ranges from 0 to 21 (21 meaning there is no disorder).

158 The 36-item form health survey (SF-36) is one of the most widely used generic questionnaires, validated in French by Perneger et al.<sup>(28)</sup>, used here to evaluate general QoL. 159 The SF-36 questionnaire consists on 36 self-administered questions (5min) divided in eight 160 161 domains, covering both physical and mental health. The physical component summary 162 covers 4 subdomains as initially described: physical functioning, role physical functioning, 163 bodily pain, and general health. The mental component summary covers 4 other domains: 164 vitality, emotional functioning, social functioning, and mental health. The sum of the score is calculated for each domain and scaled on 100. High scores indicate good QoL while low 165 166 scores indicate low QoL.

# 168 Statistical Analysis

169	To explore the evolution of quantitative variables (e.g., TDI scores) before and after
170	the OT, we employed Wilcoxon signed-rank tests, as most of the data did not follow a
171	normal distribution (as confirmed by Shapiro-Wilks tests). To compare the evolution of
172	binary variables (e.g, presence of parosmia, phantosmia), we employed McNemar test. To
173	compare quantitative variables (such as TDI scores) between different groups of participants
174	(e.g., participants with vs without parosmia) we employed Mann-Whitney tests. Non-
175	parametric correlations (Spearman rho) were employed to investigate correlations between
176	treatment compliance and improvement in TDI scores. All results were considered
177	statistically significant for a bilateral alpha level of 0,05.

#### 178 **RESULTS**

179

### 180 **Demographic and clinical features**

181 Forty-three patients were included in the study. The demographic and clinical initial182 features are reported in Table 1.

183 Patients were seen 5,8±3,2 months and 11±3,7 months after COVID-19 infection 184 respectively at the first and the second (after OT) visit. Twenty-eight patients received a 185 COVID-19 related treatment (of which 6 and 2 took respectively oral and nasal corticosteroids from 1 to 3 weeks). Among people who had a medical history of self-immune 186 187 diseases, 2 had Crohn's disease and 1 had ankylosing spondylitis. Some had a medical history of neurological diseases, 2 had epilepsy under specific medications, 1 had stroke during 188 childness with no sequelae. Nasofibroscopies found no obstructive pathologies in the 189 190 olfactory cleft.

On average, patients lost weight between the 2 visits before and after OT, going from 69,8±13,3kg to 66,7±20,1kg, but the weight reduction was not statistically significant (Z=-0,88, p=378). VAS Subjective olfactory recovery significantly increased from 34,6±26,5% to 57,9±31,1% (Z=-4,71, p<0,001). A slight, but not significant, decrease from 37 to 32 patients (74,4%) of chemosensorial complaints was reported after OT (p=0,125), with 30 (69,8%) and 5 (11,6%) patients who still suffered from flavors and/or taste loss after the OT.

197		mean	SD
157	<b>Age</b> (years)	41	13
198	Months post-COVID-19	5,8	3,2
199		n	%
	Total	43	100
200	Sex		
	Female	26	61
201	Male	17	39
202	Medical history		
	Smokers	8	18,6
203	Type II diabetes	2	4,6
	НТА	1	2,3
204	GERD	3	7
	Neurological diseases	3	7
205	Self-immune diseases	3	7
	Chronic rhinosinusitis		
206	<ul> <li>Allergic</li> </ul>	16	37,2
	<ul> <li>CRSnNP</li> </ul>	5	11,6
207	<ul> <li>CRSwNP</li> </ul>	0	0
	Neurologic diseases	3	7
208			
	COVID-19 Severity		
209	Mild to moderate illness	40	93
	Severe illness	3	7
210			
	Chemo sensorial	37	86
211	complain	<b>.</b>	
	Flavors impairment	35	81,4
212	l'aste impairment:	10	23,3

213 Table 1 – Demographics and initial clinical patients features. HTA=hypertension; GERD=gastroesophageal reflux

214 disease; CRASnNP=chronic rhinosinusitis without nasal polyps; CRASwNP=chronic rhinosinusitis with nasal

215 polyps

## 217 Olfactory training results

218 **TDI** - These was a significant improvement in the mean TDI score (Z=-4,71, p<0,001), 219 which increased from 24,7 ( $\pm$ 8,9) before the OT to 30,9 ( $\pm$ 9,8) after the OT. A significant 220 change in the number of participants categorized as anosmic, hyposmic and normosmic 221 before and after the training was found ( $Chi^2 = 25,7, p < 0,001$ ). Specifically, the number of 222 anosmic participants decreased from 10 (23,3%) to 5 (11,6%); the number of hyposmic 223 decreased from 22 (51,2%) to 11 (25,6%); and the number of normosmic participants 224 increased from 11 (25,6%) to 27 (62,8%). These results are graphically reported in Figure 1. 225 The T and I scores significantly improved after the OT (from 4,9±3,9 to 8,7±5,2, Z=-226 4,67, p<0,001; and from 9,4 $\pm$ 4,1 to 11,0 $\pm$ 3,4, Z=-3,60, p<0,001, respectively). No significant 227 evolution of the D score was observed (from  $10,4\pm3,0$  to  $11,2\pm3,3$ , Z=-1,60, p=0,110). The 228 improvement in T was significantly bigger than the improvement in D (Z=-4.1, p<0.001) and I 229 (Z = -2.7, p=0.007). T Improvement was significantly correlated with subjective recovery 230 evaluation (VAS, p=0,039). Concerning the evolution of the number of participants that 231 reached the norms for T, D, and I (based on normative datas divided by sex and age), a 232 significant increase in normalized value was only found for the T (McNemar test, p<0,001) 233 but not for the D (McNemar test, p=0,774) or the I (McNemar test, p=0,388). Based on age 234 and sex normatives values, the number of participants who had normal T, D and I before and 235 after the OT are presented in Figure 2. No clinical, medical history, treatment or compliance 236 predictive value was significantly correlated to better psychophysical tests results.

- 237
- 238
- 239
- 240



Figure 1 – Evolution of individual TDI scores before and after OT. Colored parts cover anosmic (red), hyposmic (yellow) or normosmic (green) patients according to TDI normative values<sup>(19)</sup>. Oblique lines represent a patient anosmic (red), hyposmic (yellow) or normosmic (green) subject evolution according to post OT olfactory evaluation. Solid, dashed or pointed lines represent patients who respectively did not changed category, changed to the upper category, or changed from anosmic to normosmic category.

260



Figure 2 - T, D & I normalization based on age and sex normative values. Number of patients who
normalized T, D, and I values, before and after the OT, based on age and sex normative values.

265

262

Compliance - Patients performed 14,5±9 weeks (~3,5months) of OT on average, missing
0,8±1 entire day per week, and 3±3 sessions per week. The average compliance ratio was
53±33%, ranging from 4% to 110% (for people that did more than 24 weeks). There was no
significant correlation between OT compliance and TDI evolution or subjective olfaction
evaluation recovery – VAS, or improvements in quality of life (all ps> 0,101).

**Qualitative dysosmia** - The number of participants reporting the presence of parosmia increased significantly from 8 (18,6%) to 27 (62.8%) after the OT (McNemar test, p<0,001), with only 1 participant (2%) that fully recovered after the OT, and 20 participants (46,5%) that developed parosmia after the OT. At the end of the OT, participants presenting parosmia showed lower identification scores (U= 122, p=0,018). Patients with parosmia were significantly less likely to lose weight (Z=-2,4; p=0,013). No significant difference in the number of participants reporting phantosmia was found (9 participants – 20,9% - before the

279	OT. and 12 - 27.9% - a	after the OT. p=0.	581: 8 subiects – 13	8.6% - developed	phantosmia after
2,3	OI, ana 12 27.370 0	recruice or, p o,		o,o/o acveropea	phancoshna arcer

- 280 the OT, and 5 11,6% recovered after the OT). No predictive factor was significantly
- associated with qualitative dysosmia evolution.
- 282
- 283 Quality of life The results of the SF36 and the Short-QOD-NS questionnaires are reported in
- Table 2. Concerning the SF36, significant improvements after the OT were obtained in the
- subdomains assessing physical functioning (p=0,009), social functioning (p=0,013=,
- emotional role (p=0,049), vitality (p=0,023), and general health perception (p=0,045). For the
- 287 Short-QOD-NS, significant improvements after the OT were observed for the total score
- 288 (p<0,001) and all the subdomains, namely the social (p=0.001), the food (p=0,036), the
- anxiety (p=0,020), and the annoyance (p=0,020) subdomains. Short-QOD-NS improvement
- 290 was significantly correlated to a TDI improvement after OT (p=0,008).

	BEFO	RE OT	AFTE	R OT	
Quality of life Score	Mean	ЕТ	Mean	ET	p
Short-QOD-NS					
Total score	10,44	5,97	13,65	6,49	<0,001***
Social subdomain	4,58	2,7	5,88	2,86	0,001**
Food subdomain	2,98	2,22	3,72	2,42	0,036*
Anxiety subdomain	1,91	1,02	2,44	1,12	0,020*
Annoyance subdomain	0,98	1,03	1,60	1,20	0,020*
SF36					
Physical functioning	79,53	25,42	85,81	23,20	0,009**
Social functioning	66,28	28,68	74,13	26,78	0,013*
Physical role	66,28	40,42	71,51	38,80	0,407
Emotional role	55,81	41,61	64,34	42,04	0,049*
General mental health	62,05	21,60	61,11	21,33	0,844
Vitality	44,54	24,07	51,86	21,63	0,023*
Bodily pain	66,61	31,64	69,63	33,51	0,337
General health perception	63,63	26,09	69,56	23,22	0,045*

291

292 Table 2 – Olfactory specific (Short-QOD-NS) and general (SF-36) quality of life comparative results before and

after OT. p represents the p-value at the Wilcoxon signed-rank test. \*p<0,05; \*\*p<0,01; \*\*\*p<0,001

#### 295 **DISCUSSION**

296

297 Persistent post-COVID olfactory loss is becoming a social issue as millions of people 298 worldwide are affected. OT is, for the moment, the only therapeutic hope for post-COVID-19 299 olfactory impaired patients who are still complaining of it many months after contamination, 300 despite spontaneous olfactory recovery occurring in 40<sup>(2)</sup> to 70%<sup>(4)</sup> of cases from 6 to 12 301 months. For now, only a few studies reported the OT efficiency in post-COVID-19 PPVOD.

This study reports a significant olfactory recovery after ~3,5 months of OT in PPVOD related to COVID-19. The SST MCID increased by more than 6 points<sup>(17)</sup> in average suggesting, in this situation, the OT efficiency as already knew for non-COVID-19 related PPVOD<sup>(15, 18, 24, 25)</sup>. Interestingly, we observed more than a doubling normosmic patients' ratio after OT, going from 11 (25,6%) to 27 (62,6%).

Specific to COVID-19, OT results were only reported with complete SST results in Le 307 bon et al.<sup>(29)</sup> study that compared 10 weeks of OT with (n=9) or without (n=18) a 10 days oral 308 309 corticosteroids course. In this study, there was no significant olfactory recovery in OT alone group but report 2 nonhomogeneous groups and a poor compliance for 31% of patients. 310 Olfactory subdimensions (T, D and I) specific recoveries were not reported by authors<sup>(29)</sup>. In 311 312 COVID-19 PPVOD, OT alone was reported as significantly improving olfaction recovery only 313 in other steroids efficiency evaluations studies but never again with a complete SST evaluation<sup>(30,31)</sup>. However, it is recommended<sup>(15)</sup> to integrate T, D and I studies in olfactory 314 315 evaluation. Indeed, OT effect on T, D and I in case of PPVOD is still unclear. Hummel firstly described a clear T increasing effect<sup>(17)</sup> of OT. So, according to our results, Oleszkiewicz et 316 al.<sup>(25)</sup> reported a significant increasing effect on T and I in OT efficiency on post-infectious 317 318 (n=57) and idiopathic (n=51) olfactory long lasting dysfunctions. T-recovery could be

explained by a peripheral regenerative<sup>(32)</sup> effect of OT with a regrowth of olfactory 319 neurons<sup>(33)</sup>; and I-recovery (with D-recovery) by a more central processing allowing an 320 olfaction dedicated area connectivity reorganization<sup>(23,25)</sup>. More recently, Sorokowska et 321 al.<sup>(24)</sup> reported in a meta-analysis (n>879) a large and significant post-OT increase both on D 322 and I. However, they<sup>(24)</sup> also mentioned a small to moderate effect on T, which is in 323 contradiction with our results despite that we used the same PEA threshold in both visits. 324 According to these studies<sup>(17,24,25)</sup>, in a PPVOD situation, we report an expected significant T-325 326 recovery compared to an insufficient I and D-recovery, the two last being usually correlated 327 to higher olfactory functions.

328 As potential neurological outcomes of COVID-19 PPVOD are getting more and more discussed in literature<sup>(34,35)</sup>, it could be an explanation for this lack of significant I-329 330 normalization and D-improvement. Moreover, the D is the only subdimension which did not 331 significantly improved while it's well documented that the olfactory-hippocampal network is actively involved during a discrimination learning, and so OT<sup>(36)</sup>. Discrimination and 332 333 identification tasks are closely related to cognition and specifically to executive functions, semantic task and episodic memory<sup>(37)</sup>. These cognitive functions might be affected by 334 335 hypometabolism and dysfunctioning of many parts of secondary olfactory cortex areas, or areas connected to them, reported in 18FDG PET study<sup>(38)</sup> on COVID-19 PPVOD such as : 336 337 bilateral orbito-frontal cortex, cingulate gyrus, thalamus, hippocampic or parahippocampic 338 gyri. Theses cognitives and semantic isolated impaired areas could be part of a more global 339 connectivity structure impairment suggested in a tractography study which is the inferior longitudinal fasciculus<sup>(35)</sup>. Moreover, MRI morphological (and functional) modifications of 340 341 many of these cortical areas, especially gray matter volume of cingulate gyrus and hippocampus<sup>(39)</sup>, are reported to be correlated to COVID-19 persistent ( $\geq$ 3 months) smell 342

343 loss and could be the mark of a long lasting damage of dedicated olfactory areas. Currently, 344 there is still some doubt regarding the etiology of central abnormalities observed as they are 345 not proven to be the cause or the consequences of persistent olfactory loss, but the link 346 between D and I impairment and impaired olfactory brain areas is becoming more and more 347 obvious. These central involvement in post COVID-19 persistent olfactory loss may suggest a 348 therapeutic approach consisting in the use of cognition and semantic training that could be 349 mediated by speech therapist. It has to be evaluated in the future.

350 In our study, parosmias were multiplied by 3 after OT. Parosmia physiology is 351 complex and poorly understood. It seems to be an olfactory epithelium regeneration side effect spontaneously emerging in 18%<sup>(8)</sup> to 43%<sup>(3,7)</sup> of COVID-19 PPVOD patients. Peripheral 352 353 origin is supported by an abnormal neuronal regrowth, including bad proximity neurons contacts, in a hypotrophic olfactory bulbs environment<sup>(40)</sup>. Parosmias annovance is not 354 systematic ally correlated with olfactory function justifying it occurs sometimes after a total 355 olfactory recovery in 2[here] to 20%<sup>(3)</sup>. Central origin is supported by gray matter 356 alterations<sup>(41)</sup> and olfactory cortex hypometabolism<sup>(42)</sup>. Thus, the increasing parosmic 357 patient's ratio could be linked to peripheral regeneration induced by OT, as suggested by the 358 359 significant T increase. In contrast, the persistence of this symptom could be correlated to a 360 lack of central processing suggested by the lack of I-recovery. Widely, the fact that D and I 361 did not normalize could support a central involvement explanation for persistent post-362 COVID-19 olfactory loss.

Moreover, we found that parosmic patients did not lose weight, unlike non parosmic patients. Olfaction disorders is a well-known state correlated with abnormal human control of food intake portion size and decreased reward system signals and so satiety<sup>(43)</sup>. This study supports this effect as olfactory recovery seems to be associated with a slight but not

significant loose of weight acquired during the anosmic phase. However, when parosmias occurred, this could prevent this weight loose and increase a potential metabolic risk factor associated to salt and sugar intake increased in near 30% of COVID-19 patients, especially in case of anosmia<sup>(44)</sup>.

Smell loss cause a well-known significant QoL worsening<sup>(15,45)</sup>. The benefit of such a 371 OT in COVID 19 PPVOD in still unknown but we previously reported an alteration of Short-372 QOD-NS<sup>(8)</sup>. In this study, we reported that OT not only induced significant improvement of 373 374 Short-QOD-NS, but also general QoL through SF-36 results. All Short-QOD-NS sub-scores 375 were significantly improved but mainly one related to social relationships. After a long 376 olfactory deprivation time, patients get used to it and develop strategies to cope with 377 parosmias such as avoiding food tasting or not smoke smelling. These behaviors generate 378 anxiety, and patients suffer from social network reduction. Moreover, loneliness contributes to the 30% increase of depression and suicide in this specific population<sup>(46)</sup>. The *emotional* 379 380 role and vitality SF-36 sub-domain improvements (table 2) are consistent with the fact that 381 olfaction is more than just a food sense, but also a channel for social, sexual, and emotional 382 communication. Healing from an olfactory loss seems to improve mental general state of patients. Smeets et al.<sup>(45)</sup> previously reported that all SF-36 subdimensions which improved 383 384 in our study, except general mental health, were significantly impaired in case of severe 385 dysosmia underlining the specific effect of OT on dysosmia related general QoL.

This study had however several limitations. We did not use a control group as it's often the case in OT study because it's ethically difficult not to treat a patient, and technically impossible or quite difficult to use placebo odors. Concerning TDI results, we can wonder if spontaneous recovery could have produced the same results. It's hard to answer to that question formally as, with similar complete (T,D,I) SST evaluations, there are only a

few studies reporting spontaneous post-COVID-19 olfactory recovery<sup>(47,48)</sup>, and even less 391 reporting it after OT<sup>(29)</sup>. lannuzzi et al.<sup>(49)</sup> found a significant T progression evaluated after 2 392 months of spontaneous olfactory recovery, which may correspond to early olfactory neurons 393 394 and sustentacular regeneration occurring around 2 to 4 weeks in such inflammatory  $environment^{(50)}$ . Compared to D and I, we previously reported<sup>(8)</sup> that T was the most 395 decreased olfaction subdimension measured in a cohort of patients with near 6 months 396 post-COVID-19 PPVOD, confirming what many authors found in similar patients after 4<sup>(48)</sup> or 397  $6^{(47)}$  months of spontaneous recovery with a tiny or non-significant increasing of T. There is, 398 to date, no potential explanation that could validate a spontaneous T increasing after 6 399 400 months of persistent post-COVID-19 olfactory loss. Spontaneous recovery occurred mainly in 401 the first month and does not change afterward. Another limit is the absence of psychophysical taste evaluation even if, after 6 months, almost all patients no longer 402 complained about it. Last main limit is the small sample size which can reduced the study 403 404 strength. Therefore, our SST subdimensions OT results singularity must be confirmed with 405 larger cohorts of patients.

### 406 CONCLUSION

In COVID-19 PPVOD, OT seems to significantly improve olfaction recovery, more than doubling normosmic patient' ratio. Olfaction subdimensions and qualitative dysosmias studies underline the main regenerative peripheral effect of OT as olfaction threshold significantly improved. Despite of olfaction, specific, and general patients' quality of life improvement, central involvement of persistent olfactory loss is becoming more and more significant and must be focused on future studies to improve olfactory quantitative and especially qualitative recovery.

## 414 **ACKNOWLEDGEMENTS**

- 415 Authors want to thank PAYAN BERTRAND perfumery society (28 Av. Jean XXIII, 06130 Grasse,
- 416 France) who graciously manufactured olfaction training kits given to each patient in this
- 417 study.
- 418

### 419 **AUTHORSHIP CONTRIBUTION**

- 420 CV, MP, EC, LED, AG contributed to study design, data collection, interpretation of results,
- 421 drafting and critical evaluation of the final manuscript. AP, GD, DC, ED, KR, FA, CS, NG, PR
- 422 and LC contributed to study design, interpretation of results, drafting and critical evaluation
- 423 of the final manuscript. VM contributed to biostatistics, interpretation of results and critical
- 424 evaluation of the final manuscript.
- 425

## 426 CONFLICT OF INTEREST

- 427 None declared
- 428
- 429 FUNDING
- 430 None declared
- 431

#### 432 **REFERENCES**

- 433 1. Riestra-Ayora J, Yanes-Diaz J, Esteban-Sanchez J, et al. Long-term follow-up of
- 434 olfactory and gustatory dysfunction in COVID-19: 6 months case–control study of
- 435 health workers. Eur Arch Oto-Rhino-Laryngology. 2021;278(12):4831–7.
- 436 2. Lucidi D, Molinari G, Silvestri M, et al. Patient-reported olfactory recovery after
- 437 SARS-CoV-2 infection: A 6-month follow-up study. Int Forum Allergy Rhinol.
- 438 2021;11(8):1249–52.
- 439 3. Hopkins C, Surda P, Vaira LA, et al. Six month follow-up of self-reported loss of smell

440 during the COVID-19 pandemic. Rhinol J. 2020;(11):0–0.

- 441 4. Boscolo-Rizzo P, Guida F, Polesel J, et al. Self-reported smell and taste recovery in
- 442 coronavirus disease 2019 patients: a one-year prospective study. Eur Arch Oto-Rhino-

443 Laryngology. 2022;279(1):515–20.

- 444 5. Lechien JR, Chiesa-Estomba CM, Beckers E, et al. Prevalence and 6-month recovery of
- 445 olfactory dysfunction: a multicentre study of 1363 COVID-19 patients. J Intern Med.
- 446 2021;290(2):451–61.
- 447 6. Petrocelli M, Cutrupi S, Salzano G, et al. Six-month smell and taste recovery rates in
- 448 coronavirus disease 2019 patients: A prospective psychophysical study. J Laryngol
- 449 Otol. 2021;135(5):436–41.
- 450 7. Arnaud T, Evelina T, Mats JO, et al. High prevalence of olfactory disorders 18 months
  451 after contracting COVID-19. medRxiv. 2022;
- 452 8. Vandersteen C, Payne M, Dumas L-E, et al. Persistent olfactory complaints after
- 453 COVID-19: a new interpretation of the psychophysical olfactory scores. Rhinol Online.

454 2021;4(14):66–72.

455 9. Aschenbrenner K, Hummel C, Teszmer K, et al. The Influence of Olfactory Loss on

456 Dietary Behaviors. Laryngoscope. 2008;118(1):135–44.

- 457 10. Valsamidis K, Printza A, Constantinidis J, Triaridis S. The Impact of Olfactory
- 458 Dysfunction on the Psychological Status and Quality of Life of Patients with Nasal
- 459 Obstruction and Septal Deviation. Int Arch Otorhinolaryngol. 2020;24(02):e237–46.
- 460 11. Hur K, Choi JS, Zheng M, Shen J, Wrobel B. Association of alterations in smell and taste
- 461 with depression in older adults. Laryngoscope Investig Otolaryngol. 2018;3(2):94–9.
- 462 12. Croy I, Nordin S, Hummel T. Olfactory disorders and quality of life-an updated review.
- 463 Chem Senses. 2014;39(3):185–94.
- 13. Nordin S. Sensory perception of food and ageing. In: Food for the Ageing Population.
- 465 Elsevier; 2009. p. 73–94.
- 466 14. Pence TS, Reiter ER, DiNardo LJ, Costanzo RM. Risk Factors for Hazardous Events in
  467 Olfactory-Impaired Patients. JAMA Otolaryngol Neck Surg. 2014;140(10):951.
- 468 15. Hummel T, Whitcroft KL, Andrews P, et al. Position paper on olfactory dysfunction.
- 469 Rhinol J. 2017;54(26):1–30.
- 470 16. Webster KE, O'Byrne L, MacKeith S, Philpott C, Hopkins C, Burton MJ. Interventions for
- 471 the prevention of persistent post-COVID-19 olfactory dysfunction. Cochrane Database
  472 Syst Rev. 2021;2021(8):CD013877.
- 473 17. Hummel T, Rissom K, Reden J, Hähner A, Weidenbecher M, Hüttenbrink K-B. Effects of
  474 olfactory training in patients with olfactory loss. Laryngoscope. 2009;119(3):496–9.
- 475 18. Kattar N, Do TM, Unis GD, Migneron MR, Thomas AJ, McCoul ED. Olfactory Training
- 476 for Postviral Olfactory Dysfunction: Systematic Review and Meta-analysis. Otolaryngol
  477 Neck Surg. 2021;164(2):244–54.
- 478 19. Oleszkiewicz A, Schriever VA, Croy I, Hähner A, Hummel T. Updated Sniffin' Sticks
  479 normative data based on an extended sample of 9139 subjects. Eur Arch Oto-Rhino-

480 Laryngology. 2019;276(3):719–28.

- 481 20. Leclercq C, Chiesa-Estomba CM, Horoi M, et al. Validity and Reliability of the French 482 Short Version of the Questionnaire of Olfactory Disorders-Negative Statements (sQOD-NS). Ear, Nose Throat J. 2021;014556132110320. 483 484 21. Leplège A, Ecosse E, Coste J, Pouchot J, Perneger T. Le questionnaire MOS SF-36: 485 manuel de l'utilisateur et guide d'interprétation des scores. Paris: Editions ESTEM; 486 2001. 156 p. 487 22. Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G. 'Sniffin' Sticks': Olfactory 488 Performance Assessed by the Combined Testing of Odour Identification, Odor 489 Discrimination and Olfactory Threshold. Chem Senses. 1997;22(1):39-52. 490 23. Kollndorfer K, Fischmeister FPS, Kowalczyk K, et al. Olfactory training induces changes 491 in regional functional connectivity in patients with long-term smell loss. NeuroImage 492 Clin. 2015;9:401–10. 493 24. Sorokowska A, Drechsler E, Karwowski M, Hummel T. Effects of olfactory training: a 494 meta-analysis. Rhinol J. 2017;55(1):17-26. 495 25. Oleszkiewicz A, Hanf S, Whitcroft KL, Haehner A, Hummel T. Examination of olfactory 496 training effectiveness in relation to its complexity and the cause of olfactory loss.
  - 497 Laryngoscope. 2018;128(7):1518–22.
  - 498 26. Simopoulos E, Katotomichelakis M, Gouveris H, Tripsianis G, Livaditis M, Danielides V.
  - 499 Olfaction-associated quality of life in chronic rhinosinusitis: Adaptation and validation
  - 500 of an olfaction-specific questionnaire. Laryngoscope. 2012;122(7):1450–4.
  - 501 27. Mattos JL, Edwards C, Schlosser RJ, et al. A brief version of the questionnaire of
  - 502 olfactory disorders in patients with chronic rhinosinusitis. Int Forum Allergy Rhinol.

503 2019;9(10):1144–50.

504	28.	Perneger T V.	, Leplège A,	Etter J-F,	Rougemont A.	Validation of a	French-lang	Jage
			, , , , ,					

- version of the MOS 36-Item Short Form Health Survey (SF-36) in young healthy adults.
- 506 J Clin Epidemiol. 1995;48(8):1051–60.
- 507 29. Le Bon S-D, Konopnicki D, Pisarski N, Prunier L, Lechien JR, Horoi M. Efficacy and
- safety of oral corticosteroids and olfactory training in the management of COVID-19-
- related loss of smell. Eur Arch Oto-Rhino-Laryngology. 2021;278(8):3113–7.
- 510 30. Saussez S, Vaira LA, Chiesa-Estomba CM, et al. Short-term efficacy and safety of oral
- and nasal corticosteroids in covid-19 patients with olfactory dysfunction: A European
- 512 multicenter study. Pathogens. 2021;10(6):1–14.
- 513 31. Abdelalim AA, Mohamady AA, Elsayed RA, Elawady MA, Ghallab AF. Corticosteroid
- 514 nasal spray for recovery of smell sensation in COVID-19 patients: A randomized
- 515 controlled trial. Am J Otolaryngol. 2021;42(2):102884.
- 516 32. Ojha P, Dixit A. Olfactory training for olfactory dysfunction in COVID-19: A promising
- 517 mitigation amidst looming neurocognitive sequelae of the pandemic. Clin Exp
- 518 Pharmacol Physiol. 2022;(September 2021):1–12.
- 519 33. Hummel T, Stupka G, Haehner A, Poletti SC. Olfactory training changes
- 520 electrophysiological responses at the level of the olfactory epithelium. Rhinology.
- 521 2018;56(4):330-5.
- 522 34. Meinhardt J, Radke J, Dittmayer C, et al. Olfactory transmucosal SARS-CoV-2 invasion
- 523 as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci.
- 524 2021;24(2):168–75.
- 525 35. Donegani MI, Miceli A, Pardini M, et al. Brain Metabolic Correlates of Persistent
- 526 Olfactory Dysfunction after SARS-Cov2 Infection. Biomedicines. 2021;9(3):287.
- 527 36. Martin C, Beshel J, Kay LM. An Olfacto-Hippocampal Network Is Dynamically Involved

528		in Odor-Discrimination Learning. J Neurophysiol. 2007;98(4):2196–205.
529	37.	Hedner M, Larsson M, Arnold N, Zucco GM, Hummel T. Cognitive factors in odor
530		detection, odor discrimination, and odor identification tasks. J Clin Exp Neuropsychol.
531		2010;32(10):1062-7.
532	38.	Karimi-Galougahi M, Yousefi-Koma A, Bakhshayeshkaram M, Raad N, Haseli S. 18FDG
533		PET/CT Scan Reveals Hypoactive Orbitofrontal Cortex in Anosmia of COVID-19. Acad
534		Radiol. 2020;27(7):1042–3.
535	39.	Lu Y, Li X, Geng D, et al. Cerebral Micro-Structural Changes in COVID-19 Patients – An
536		MRI-based 3-month Follow-up Study. EClinicalMedicine. 2020;25(2):100484.
537	40.	Parker JK, Kelly CE, Gane SB. Molecular Mechanism of Parosmia. medRxiv.
538		2021;2021.02.05.21251085.
539	41.	Bitter T, Siegert F, Gudziol H, et al. Gray matter alterations in parosmia. Neuroscience.
540		2011;177:177-82.
541	42.	Iannilli E, Leopold DA, Hornung DE, Hummel T. Advances in Understanding Parosmia:
542		An fMRI Study. ORL. 2019;81(4):185–92.
543	43.	Meunier N, Briand L, Jacquin-Piques A, Brondel L, Pénicaud L. COVID 19-Induced Smell
544		and Taste Impairments: Putative Impact on Physiology. Front Physiol.
545		2021;11(January):1–12.
546	44.	Vandersteen C, Payne M, Dumas LÉ, et al. What about using sniffin' sticks 12 items
547		test to screen post-COVID-19 olfactory disorders? Eur Arch Oto-Rhino-Laryngology.

- 548 2021;
- 549 45. Smeets MAM, Veldhuizen MG, Galle S, et al. Sense of Smell Disorder and Health-

550 Related Quality of Life. Rehabil Psychol. 2009;54(4):404–12.

551 46. Yom-Tov E, Lekkas D, Jacobson NC. Association of COVID19-induced anosmia and

552 ageusia with depression and suicidal ideation. J Attect D	ct Disord Reports.
---	--------------------

553	2021;5(January):100156.
-----	-------------------------

- 47. Bordin A, Mucignat-Caretta C, Gaudioso P, et al. Comparison of self-reported
- 555 symptoms and psychophysical tests in coronavirus disease 2019 (COVID-19) subjects
- 556 experiencing long-term olfactory dysfunction: a 6-month follow-up study. Int Forum
- 557 Allergy Rhinol. 2021;11(11):1592–5.
- 558 48. Niklassen AS, Draf J, Huart C, et al. COVID-19: Recovery from Chemosensory
- 559 Dysfunction. A Multicentre study on Smell and Taste. Laryngoscope.
- 560 2021;131(5):1095**-**100.
- 49. Iannuzzi L, Salzo AE, Angarano G, et al. Gaining Back What Is Lost: Recovering the
- 562 Sense of Smell in Mild to Moderate Patients After COVID-19. Chem Senses.
- 563 2020;45(9):875-81.
- 564 50. de Melo GD, Lazarini F, Levallois S, et al. COVID-19–related anosmia is associated with
- 565 viral persistence and inflammation in human olfactory epithelium and brain infection
- in hamsters. Sci Transl Med. 2021;13(596).



